Literature DB >> 22673621

Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting.

Sudarsanareddy Lokireddy1, Isuru Wijerupage Wijesoma, Siu Kwan Sze, Craig McFarlane, Ravi Kambadur, Mridula Sharma.   

Abstract

Atrogin-1, a muscle-specific E3 ligase, targets MyoD for degradation through the ubiquitin-proteasome-mediated system. Myostatin, a member of the transforming growth factor-β superfamily, potently inhibits myogenesis by lowering MyoD levels. While atrogin-1 is upregulated by myostatin, it is currently unknown whether atrogin-1 plays a role in mediating myostatin signaling to regulate myogenesis. In this report, we have confirmed that atrogin-1 increasingly interacts with MyoD upon recombinant human myostatin (hMstn) treatment. The absence of atrogin-1, however, led to elevated MyoD levels and permitted the differentiation of atrogin-1(-/-) primary myoblast cultures despite the presence of exogenous myostatin. Furthermore, inactivation of atrogin-1 rescued myoblasts from growth inhibition by hMstn. Therefore, these results highlight the central role of atrogin-1 in regulating myostatin signaling during myogenesis. Currently, there are only two known targets of atrogin-1. Thus, we next characterized the associated proteins of atrogin-1 in control and hMstn-treated C2C12 cell cultures by stably expressing tagged atrogin-1 in myoblasts and myotubes, and sequencing the coimmunoprecipitated proteome. We found that atrogin-1 putatively interacts with sarcomeric proteins, transcriptional factors, metabolic enzymes, components of translation, and spliceosome formation. In addition, we also identified that desmin and vimentin, two components of the intermediate filament in muscle, directly interacted with and were degraded by atrogin-1 in response to hMstn. In summary, the muscle wasting effects of the myostatin-atrogin-1 axis are not only limited to the degradation of MyoD and eukaryotic translation initiation factor 3 subunit f, but also encompass several proteins that are involved in a wide variety of cellular activities in the muscle.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22673621     DOI: 10.1152/ajpcell.00402.2011

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  42 in total

1.  Effects of ageing on expression of the muscle-specific E3 ubiquitin ligases and Akt-dependent regulation of Foxo transcription factors in skeletal muscle.

Authors:  Akira Wagatsuma; Masataka Shiozuka; Yuzo Takayama; Takayuki Hoshino; Kunihiko Mabuchi; Ryoichi Matsuda
Journal:  Mol Cell Biochem       Date:  2015-11-20       Impact factor: 3.396

Review 2.  FoxO transcription factors: their roles in the maintenance of skeletal muscle homeostasis.

Authors:  Anthony M J Sanchez; Robin B Candau; Henri Bernardi
Journal:  Cell Mol Life Sci       Date:  2014-05       Impact factor: 9.261

3.  Characterization of Optimal Strain, Frequency and Duration of Mechanical Loading on Skeletal Myotubes' Biological Responses.

Authors:  Athanasios Moustogiannis; Anastassios Philippou; Evangelos Zevolis; Orjona Taso; Antonios Chatzigeorgiou; Michael Koutsilieris
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

4.  Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo.

Authors:  Craig A Goodman; Rachel M McNally; F Michael Hoffmann; Troy A Hornberger
Journal:  Mol Endocrinol       Date:  2013-09-03

5.  SMAD3 augments FoxO3-induced MuRF-1 promoter activity in a DNA-binding-dependent manner.

Authors:  Lance M Bollinger; Carol A Witczak; Joseph A Houmard; Jeffrey J Brault
Journal:  Am J Physiol Cell Physiol       Date:  2014-06-11       Impact factor: 4.249

6.  Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation.

Authors:  Nobuyuki Tanaka; Takeo Kosaka; Yasumasa Miyazaki; Shuji Mikami; Naoya Niwa; Yutaro Otsuka; Yoji Andrew Minamishima; Ryuichi Mizuno; Eiji Kikuchi; Akira Miyajima; Hisataka Sabe; Yasunori Okada; Per Uhlén; Makoto Suematsu; Mototsugu Oya
Journal:  JCI Insight       Date:  2016-11-03

Review 7.  Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1.

Authors:  Sue C Bodine; Leslie M Baehr
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-05       Impact factor: 4.310

Review 8.  Mitochondrial dysfunction induces muscle atrophy during prolonged inactivity: A review of the causes and effects.

Authors:  Hayden Hyatt; Rafael Deminice; Toshinori Yoshihara; Scott K Powers
Journal:  Arch Biochem Biophys       Date:  2018-11-16       Impact factor: 4.013

9.  MAFbx/Atrogin-1 is required for atrophic remodeling of the unloaded heart.

Authors:  Kedryn K Baskin; Meredith R Rodriguez; Seema Kansara; Wenhao Chen; Sylvia Carranza; O Howard Frazier; David J Glass; Heinrich Taegtmeyer
Journal:  J Mol Cell Cardiol       Date:  2014-03-18       Impact factor: 5.000

Review 10.  Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways.

Authors:  J Rodriguez; B Vernus; I Chelh; I Cassar-Malek; J C Gabillard; A Hadj Sassi; I Seiliez; B Picard; A Bonnieu
Journal:  Cell Mol Life Sci       Date:  2014-07-31       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.